Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 7:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2593–2616 of 22,555 matching trials from the live ClinicalTrials.gov search.
Conditions
Leukemia, Lymphoma, Tumor Lysis Syndrome, Hyperuricemia
Interventions
Rasburicase
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
11
States / cities
Palo Alto, California • San Diego, California • Indianapolis, Indiana + 8 more
Conditions
Locally Advanced (Unresectable) or Metastatic Solid Tumors
Interventions
NEOK002, NEOK002 RDE
Drug
Lead sponsor
NEOK Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
10
States / cities
Orlando, Florida • New York, New York • Nashville, Tennessee + 5 more
Completed Phase 3 Interventional Results available

Study of Antidepressants in Parkinson's Disease

NCT00086190
Conditions
Parkinson Disease, Depression
Interventions
paroxetine, venlafaxine, placebo
Drug · Other
Lead sponsor
University of Rochester
Other
Eligibility
30 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
15
States / cities
San Francisco, California • Gainesville, Florida • Miami, Florida + 11 more
Conditions
Atopic Dermatitis
Interventions
DMT210 Topical Gel, Vehicle Control
Drug
Lead sponsor
Dermata Therapeutics
Industry
Eligibility
12 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Houston, Texas • Norfolk, Virginia
Conditions
Acute Ischaemic Stroke, Transient Ischaemic Attack
Interventions
ticagrelor, Acetylsalicylic acid (ASA)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
13,307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
115
States / cities
Montgomery, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 112 more
Conditions
Stress Disorders, Post-Traumatic, Sleep Disorders
Interventions
MEDVAMC Nightmare Treatment, Telepsychiatry Nightmare Treatment
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 64 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Houston, Texas
Conditions
Radiographic Contrast Agent Nephropathy
Interventions
CINCOR™ System and contrast conservation unit (CCS-1), Standard of Care plus peri-procedural hydration
Device · Other
Lead sponsor
Osprey Medical, Inc
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
20
States / cities
Huntsville, Alabama • Phoenix, Arizona • Los Angeles, California + 17 more
Conditions
Diabetes Mellitus, Type 2
Interventions
albiglutide, insulin glargine
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
779 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
314
States / cities
Alabaster, Alabama • Birmingham, Alabama • Dothan, Alabama + 252 more
Conditions
Nurse's Role, Nurse-Patient Relations, Satisfaction, Patient Fall
Interventions
Rehab MATRIX
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Houston, Texas
Conditions
Glioblastoma Multiforme
Interventions
ICT-107, Placebo DC
Biological
Lead sponsor
Precision Life Sciences Group
Industry
Eligibility
18 Years to 80 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
25
States / cities
South Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 17 more
Conditions
Shoulder and Upper Arm Injury
Interventions
Not listed
Lead sponsor
Texas Woman's University
Other
Eligibility
18 Years to 30 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Houston, Texas
Conditions
Crohn Disease
Interventions
Ozanimod
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 75 Years
Enrollment
854 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
190
States / cities
Peoria, Arizona • Scottsdale, Arizona • North Little Rock, Arkansas + 142 more
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
Interventions
Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration, Waiting List
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Multiple Myeloma
Interventions
BMS-986393, Alnuctamab, Mezigdomide, Iberdomide, Elranatamab, Dexamethasone
Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 11 more
Conditions
Chronic Idiopathic Constipation
Interventions
Elobixibat 10 mg
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
53
States / cities
Tucson, Arizona • Little Rock, Arkansas • North Little Rock, Arkansas + 46 more
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Extended Release Methylphenidate (Ritalin LA ) plus Behavior Therapy, Behavior Therapy
Drug · Behavioral
Lead sponsor
Novartis
Industry
Eligibility
6 Years to 12 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Houston, Texas
Conditions
Fatigue
Interventions
Methylphenidate, Fatigue Evaluations
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2021
U.S. locations
1
States / cities
Houston, Texas
Conditions
Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer, Locally Advanced Solid Tumor
Interventions
NTX-1088, Pembrolizumab
Drug
Lead sponsor
Nectin Therapeutics Ltd
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Duarte, California • New Orleans, Louisiana • Houston, Texas
Conditions
Aortic Arch Aneurysm, Aortic Arch Dissection, Chronic Aortic Dissection, Acute Aortic Dissection
Interventions
Arcevo™ LSA Hybrid Stent Graft System
Device
Lead sponsor
Artivion Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 16 more
Conditions
Systemic Lupus Erythematosus
Interventions
Placebo, PF-06700841 15 mg, PF-06700841 30 mg, PF-06700841 45 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
55
States / cities
Birmingham, Alabama • Fullerton, California • La Palma, California + 34 more
Completed Phase 1Phase 2 Interventional Results available

Erythropoetin Neuroprotection for Neonatal Cardiac Surgery

NCT00513240
Conditions
Congenital Heart Disease, Hypoplastic Left Heart Syndrome, Transposition of the Great Arteries, Aortic Arch Hypoplasia or Interruption
Interventions
Erythropoetin, Normal saline
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Day to 30 Days
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Houston, Texas
Conditions
Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia
Interventions
Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Busulfan, Clofarabine, Fludarabine Phosphate, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Vorinostat
Procedure · Biological · Drug + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 60 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Houston, Texas
Conditions
Hepatitis C, Genotype 1
Interventions
Daclatasvir, Ribavirin, PEG-Interferon alfa 2a
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
23
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 18 more
Conditions
Heavy Menstrual Bleeding, Uterine Fibroid
Interventions
Relugolix, Estradiol/norethindrone acetate
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
104
States / cities
Andalusia, Alabama • Birmingham, Alabama • Mobile, Alabama + 84 more